Literature DB >> 29383713

Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).

Lars H Lindner1, Saskia Litière2, Stefan Sleijfer3, Charlotte Benson4, Antoine Italiano5, Bernd Kasper6, Christina Messiou4, Hans Gelderblom7, Eva Wardelmann8, Axel Le Cesne9, Jean-Yves Blay10, Sandrine Marreaud2, Nadia Hindi11, Ingrid M E Desar12, Alessandro Gronchi13, Winette T A van der Graaf4,14.   

Abstract

The prognosis of adult soft tissue sarcoma (STS) patients with metastases is generally poor. As little is known about the impact of the involvement of different metastatic sites and the extent of pulmonary lesions on the outcome for patients receiving first-line chemotherapy, we aimed to establish prognostic factors for STS patients with lung metastases only. A retrospective, exploratory analysis was performed on 2,913 metastatic STS patients who received first-line chemotherapy. Detailed information from 580 patients who had lung metastases only, was used for prognostic factor analysis. Patients with lung metastases only were more often asymptomatic and had undergone complete primary tumor resection more frequently compared to patients with additional metastases outside the lung or without lung metastases. For extremity STS, the incidence of lung metastases only was much higher compared to non-extremity STS. Lung involvement only was an independent favorable prognostic factor for overall survival (OS) with regard to metastatic site. Within this subgroup, in a multivariate model, other factors associated with improved OS included: good performance status (PS), no progression at primary site, low histological grade, younger age, long interval between initial diagnosis and trial registration, and smaller diameter of the largest lung lesion. This unique analysis on prognostic factors in STS patients with lung metastases confirms well-known patient factors (such as age and PS), and tumor characteristics (including tumor grade, interval between primary diagnosis, and metastases), but also identifies diameter of the largest lung lesion as a new prognostic factor. Knowledge about these factors may support decision-making within multidisciplinary tumor boards.
© 2018 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Entities:  

Keywords:  EORTC; lung metastases; prognostic factors; soft tissue sarcoma

Mesh:

Year:  2018        PMID: 29383713      PMCID: PMC5947111          DOI: 10.1002/ijc.31286

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  28 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma.

Authors:  Anastasia Constantinidou; Winette T A van der Graaf
Journal:  Eur J Cancer       Date:  2017-08-23       Impact factor: 9.162

3.  Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities.

Authors:  P W Pisters; D H Leung; J Woodruff; W Shi; M F Brennan
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

4.  Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma.

Authors:  P W Pisters; L B Harrison; D H Leung; J M Woodruff; E S Casper; M F Brennan
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

5.  Incidence and survival in sarcoma in the United States: a focus on musculoskeletal lesions.

Authors:  Vincent Y Ng; Thomas J Scharschmidt; Joel L Mayerson; James L Fisher
Journal:  Anticancer Res       Date:  2013-06       Impact factor: 2.480

6.  Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival.

Authors:  K G Billingsley; M E Burt; E Jara; R J Ginsberg; J M Woodruff; D H Leung; M F Brennan
Journal:  Ann Surg       Date:  1999-05       Impact factor: 12.969

7.  Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer.

Authors:  L Sengeløv; C Kamby; P Geertsen; L J Andersen; H von der Maase
Journal:  Cancer Chemother Pharmacol       Date:  2000       Impact factor: 3.333

8.  High-grade soft tissue sarcomas of the extremities.

Authors:  D A Potter; T Kinsella; E Glatstein; R Wesley; D E White; C A Seipp; A E Chang; E E Lack; J Costa; S A Rosenberg
Journal:  Cancer       Date:  1986-07-01       Impact factor: 6.860

9.  Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group.

Authors:  M Toulmonde; S Bonvalot; I Ray-Coquard; E Stoeckle; O Riou; N Isambert; E Bompas; N Penel; C Delcambre-Lair; E Saada; A Lecesne; C Le Péchoux; J Y Blay; S Piperno-Neumann; C Chevreau; J O Bay; V Brouste; P Terrier; D Ranchère-Vince; A Neuville; A Italiano
Journal:  Ann Oncol       Date:  2014-02-03       Impact factor: 32.976

10.  The role of multimodality therapy in soft-tissue sarcoma.

Authors:  M F Brennan; E S Casper; L B Harrison; M H Shiu; J Gaynor; S I Hajdu
Journal:  Ann Surg       Date:  1991-09       Impact factor: 12.969

View more
  16 in total

1.  The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study.

Authors:  Tomoki Nakamura; Satoshi Tsukushi; Kunihiro Asanuma; Hirohisa Katagiri; Kunihiro Ikuta; Akihito Nagano; Eiji Kozawa; Satoshi Yamada; Yoji Shido; Kenji Yamada; Katsuhisa Kawanami; Daisuke Ishimura; Akihiro Sudo; Yoshihiro Nishida
Journal:  Clin Exp Metastasis       Date:  2019-06-17       Impact factor: 5.150

2.  The Long Noncoding RNA NEAT1 Promotes Sarcoma Metastasis by Regulating RNA Splicing Pathways.

Authors:  Jianguo Huang; Mohit Sachdeva; Eric Xu; Timothy J Robinson; Lixia Luo; Yan Ma; Nerissa T Williams; Omar Lopez; Lisa D Cervia; Fan Yuan; Xiaodi Qin; Dadong Zhang; Kouros Owzar; Nalan Gokgoz; Andrew Seto; Tomoyo Okada; Samuel Singer; Irene L Andrulis; Jay S Wunder; Alexander J Lazar; Brian P Rubin; Krista Pipho; Stephano S Mello; Jimena Giudice; David G Kirsch
Journal:  Mol Cancer Res       Date:  2020-06-19       Impact factor: 5.852

3.  Is Metformin Use Associated with Prolonged Overall Survival in Patients with Soft Tissue Sarcoma? A SEER-Medicare Study.

Authors:  Ian D Hutchinson; Ashar Ata; Matthew R DiCaprio
Journal:  Clin Orthop Relat Res       Date:  2022-04-01       Impact factor: 4.755

4.  Is Surgical Resection of the Primary Site Associated with an Improved Overall Survival for Patients with Primary Malignant Bone Tumors Who Have Metastatic Disease at Presentation?

Authors:  Azeem Tariq Malik; John H Alexander; Joel L Mayerson; Safdar N Khan; Thomas J Scharschmidt
Journal:  Clin Orthop Relat Res       Date:  2020-10       Impact factor: 4.755

5.  Very long-term survivors among patients with metastatic soft tissue sarcoma.

Authors:  Mélodie Carbonnaux; Mehdi Brahmi; Camille Schiffler; Pierre Meeus; Marie-Pierre Sunyach; Amine Bouhamama; Marie Karanian; Franck Tirode; Daniel Pissaloux; Gualter Vaz; Isabelle Ray-Coquard; Jean-Yves Blay; Armelle Dufresne
Journal:  Cancer Med       Date:  2019-03-27       Impact factor: 4.452

6.  Score for the Risk and Overall Survival of Lung Metastasis in Patients First Diagnosed With Soft Tissue Sarcoma: A Novel Nomogram-Based Risk Assessment System.

Authors:  Zhiyi Fan; Changxing Chi; Yuexin Tong; Zhangheng Huang; Youxin Song; Shengjie You
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 7.  2018 ESMO Sarcoma and GIST Symposium: 'take-home messages' in soft tissue sarcoma.

Authors:  Anna Maria Frezza; Alex T J Lee; Eran Nizri; Marta Sbaraglia; Robin L Jones; Alessandro Gronchi; Angelo Paolo Dei Tos; Paolo G Casali
Journal:  ESMO Open       Date:  2018-06-28

8.  Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study.

Authors:  Zhichao Tian; Yonghao Yang; Jinpo Yang; Peng Zhang; Fan Zhang; Xinhui Du; Chao Li; Jiaqiang Wang
Journal:  Cancer Manag Res       Date:  2020-02-24       Impact factor: 3.989

9.  Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic.

Authors:  Javier Martin-Broto; Nadia Hindi; Samuel Aguiar; Ronald Badilla-González; Victor Castro-Oliden; Matias Chacón; Raquel Correa-Generoso; Enrique de Álava; Davide María Donati; Mikael Eriksson; Martin Falla-Jimenez; Gisela German; Maria Leticia Gobo Silva; Francois Gouin; Alessandro Gronchi; Juan Carlos Haro-Varas; Natalia Jiménez-Brenes; Bernd Kasper; Celso Abdon Lopes de Mello; Robert Maki; Paula Martínez-Delgado; Hector Martínez-Said; Jorge Luis Martinez-Tlahuel; Jose Manuel Morales-Pérez; Francisco Cristobal Muñoz-Casares; Suely A Nakagawa; Eduardo Jose Ortiz-Cruz; Emanuela Palmerini; Shreyaskumar Patel; David S Moura; Silvia Stacchiotti; Marie Pierre Sunyach; Claudia M Valverde; Federico Waisberg; Jean-Yves Blay
Journal:  Oncologist       Date:  2020-09-23       Impact factor: 5.837

10.  Nomogram for predicting the overall survival and cancer-specific survival of patients with extremity liposarcoma: a population-based study.

Authors:  Lin Ye; Chuan Hu; Cailin Wang; Weiyang Yu; Feijun Liu; Zhenzhong Chen
Journal:  BMC Cancer       Date:  2020-09-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.